{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:35:25Z","timestamp":1791318925525,"version":"4.3.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,2,18]],"date-time":"2009-02-18T00:00:00Z","timestamp":1234915200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1007\/s00280-008-0922-4","type":"journal-article","created":{"date-parts":[[2009,2,17]],"date-time":"2009-02-17T08:58:03Z","timestamp":1234861083000},"page":"733-740","source":"Crossref","is-referenced-by-count":31,"title":["Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma"],"prefix":"10.1007","volume":"64","author":[{"given":"Pooja","family":"Hingorani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajida","family":"Piperdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyna","family":"Pressman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Gorlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Anders","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,2,18]]},"reference":[{"key":"922_CR1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/03602530500364023","volume":"37","author":"J Zhang","year":"2004","unstructured":"Zhang J, Tian Q, Yung Chan S, Cheun Li S, Zhou S, Duan W, Zhu YZ (2004) Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab Rev 37:611\u2013703","journal-title":"Drug Metab Rev"},{"key":"922_CR2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00280-001-0412-4","volume":"49","author":"NE Sladek","year":"2002","unstructured":"Sladek NE, Kollander R, Sreerama L, Kiang DT (2002) Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide- based chemotherapy of breast cancer: a retrospective study. Cancer Chemother Pharmacol 49:309\u2013321","journal-title":"Cancer Chemother Pharmacol"},{"key":"922_CR3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s002800000208","volume":"47","author":"L Sreerama","year":"2001","unstructured":"Sreerama L, Sladek NE (2001) Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants. Rational individualization of cancer chemotherapeutic regimens. Cancer Chemother Pharmacol 47:255\u2013262","journal-title":"Cancer Chemother Pharmacol"},{"key":"922_CR4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00280-006-0233-6","volume":"59","author":"JS Moreb","year":"2007","unstructured":"Moreb JS, Muhoczy D, Ostmark B, Zucali JR (2007) RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. Cancer Chemother Pharmacol 59:127\u2013136","journal-title":"Cancer Chemother Pharmacol"},{"key":"922_CR5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/PL00006744","volume":"45","author":"RF Struck","year":"2000","unstructured":"Struck RF, Davis RL Jr, Berardini MD, Loechler EL (2000) DNA guanine\u2013guanine crosslinking sequence specificity of isophosphoramide mustard, the alkylating metabolite of the clinical antitumor agent ifosfamide. Cancer Chemother Pharmacol 45:59\u201362","journal-title":"Cancer Chemother Pharmacol"},{"key":"922_CR6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00280-004-0894-y","volume":"55","author":"N Germann","year":"2005","unstructured":"Germann N, Urien S, Rodgers AH, Ratterree M, Struck RF, Waud WR, Serota DG, Bastian G, Jursic BS, Morgan LR (2005) Comparative preclinical toxicology and pharmacology of isophosphoramide mustard, the active metabolite of ifosfamide. Cancer Chemother Pharmacol 55:143\u2013151","journal-title":"Cancer Chemother Pharmacol"},{"key":"922_CR7","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/pbc.21078","volume":"49","author":"PJ Houghton","year":"2007","unstructured":"Houghton PJ, Morton CL, Tucker C, Gorlick R, Kolb EA, Zhang W, Smith MA (2007) The Pediatric Preclinical Testing Program: description of models and early testing results. Pediatr Blood Cancer 49:928\u2013940","journal-title":"Pediatr Blood Cancer"},{"key":"922_CR8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1124\/jpet.104.072496","volume":"312","author":"JS Moreb","year":"2005","unstructured":"Moreb JS, Gabr A, Vartikar GR, Gowda S, Zucali JR, Mohuczy D (2005) Retinoic acid down-regulates aldehyde dehydrogenase and increases cytotoxicity of 4-hydroperoxycyclophosphamide and acetaldehyde. J Pharmacol Exp Ther 312:339\u2013345","journal-title":"J Pharmacol Exp Ther"},{"key":"922_CR9","first-page":"1901","volume":"3","author":"L Sreerama","year":"1997","unstructured":"Sreerama L, Sladek NE (1997) Cellular levels of class 1 and class 3 aldehyde dehydrogenases and certain other drug metabolizing enzymes in human breast malignancies. Clin Cancer Res 3:1901\u20131914","journal-title":"Clin Cancer Res"},{"key":"922_CR10","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/0006-2952(94)90593-2","volume":"48","author":"GK Rekha","year":"1994","unstructured":"Rekha GK, Sreerama L, Sladek NE (1994) Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class 3 aldehyde dehydrogenase. Biochem Pharmacol 48:1943\u20131952","journal-title":"Biochem Pharmacol"},{"key":"922_CR11","first-page":"5373","volume":"52","author":"HS Friedman","year":"1992","unstructured":"Friedman HS, Colvin M, Kaufmann SH, Ludeman SM, Bullock N, Bigner DD, Griffith OW (1992) Cyclophosphamide resistance in medulloblastoma. Cancer Res 52:5373\u20135378","journal-title":"Cancer Res"},{"key":"922_CR12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2174\/156800906777723967","volume":"6","author":"J Zhang","year":"2006","unstructured":"Zhang J, Tian Q, Zhu YZ, Xu AL, Zhou SF (2006) Reversal of resistance to oxazaphosphorines. Curr Cancer Drug Targets 6:385\u2013407","journal-title":"Curr Cancer Drug Targets"},{"key":"922_CR13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.drup.2005.08.003","volume":"8","author":"J Zhang","year":"2005","unstructured":"Zhang J, Tian Q, Chan SY, Duan W, Zhou S (2005) Insights into oxazaphosphorine resistance and possible approaches to its circumvention. Drug Resist Updat 8:271\u2013297","journal-title":"Drug Resist Updat"},{"key":"922_CR14","first-page":"9524","volume":"24","author":"R Gale","year":"2006","unstructured":"Gale R, Van Vugt A, Rosen L, Chang L, Lorusso P, Valdivieso M, Malburg L, Struck R, Morgan L (2006) Phase-1 study of isophosphoramide (IPM)-lysine in advanced cancers. ASCO Annu Meet Proc 24:9524","journal-title":"ASCO Annu Meet Proc"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0922-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-008-0922-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0922-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T06:06:56Z","timestamp":1559023616000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-008-0922-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,18]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["922"],"URL":"https:\/\/doi.org\/10.1007\/s00280-008-0922-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,18]]}}}